Zoetis Inc. (ZTS) EV/EBIT Ratio: 11.42x
Is Zoetis Inc.’s EV/EBIT ratio high or low?
Zoetis Inc.'s EV/EBIT ratio of 11.42x is 58% below its 5-year average of 27.31x, near the low end of its 5-year range (10.82x–44.54x).
As of Wednesday, June 17, 2026. 35.56% below its 12-month average of 17.72x.
ZTS EV/EBIT Ratio Chart
ZTS Average EV/EBIT Ratio Chart
ZTS Current vs Average EV/EBIT Ratio Chart
ZTS EV/EBIT Ratio Metrics
EV/EBIT RATIO
11.42x
EV/EBIT RATIO AVG TTM
17.72x
EV/EBIT RATIO AVG 3Y
23.94x
EV/EBIT RATIO AVG 5Y
27.47x
EV/EBIT RATIO AVG 10Y
28.14x
EV/EBIT RATIO AVG 15Y
N/A
EV/EBIT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-35.56%
CURRENT VS 3Y AVG
-52.29%
CURRENT VS 5Y AVG
-58.42%
CURRENT VS 10Y AVG
-59.42%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
ZTS Competitors' EV/EBIT Ratio
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zoetis Inc. (ZTS) | $33.26B | 11.42x | 17.72x | 23.94x | 27.47x |
| Medline Inc. (MDLN)vs › | $30.65B | 20.00x | 21.19x | 21.19x | 21.19x |
| Agilent Technologies, Inc. (A)vs › | $36.04B | 24.44x | 26.25x | 27.13x | 28.87x |
| Centene Corporation (CNC)vs › | $30.31B | N/A | 10.37x | 16.91x | 20.65x |
| IQVIA Holdings Inc. (IQV)vs › | $29.90B | 19.32x | 21.04x | 24.19x | 30.02x |
| Biogen Inc. (BIIB)vs › | $28.88B | 20.88x | 13.42x | 14.82x | 15.74x |
| DexCom, Inc. (DXCM)vs › | $28.23B | 28.12x | 38.30x | 64.71x | 101.59x |
| Veeva Systems Inc. (VEEV)vs › | $25.96B | 26.50x | 45.02x | 60.39x | 66.05x |
| Waters Corporation (WAT)vs › | $23.53B | 53.92x | 27.99x | 26.69x | 26.31x |
| United Therapeutics Corporation (UTHR)vs › | $23.41B | 17.36x | 13.86x | 11.89x | 13.34x |
Zoetis Inc. EV/EBIT Ratio Formula & Definition
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Zoetis Inc. EV/EBIT Ratio FAQ
- What is the EV/EBIT ratio for Zoetis Inc. (ZTS)?
- The EV/EBIT ratio for ZTS stock is 11.42x.
- Is Zoetis Inc.'s EV/EBIT ratio high or low?
- Zoetis Inc.'s EV/EBIT ratio of 11.42x is 58% below its 5-year average of 27.31x, near the low end of its 5-year range (10.82x–44.54x).
- What is the TTM average EV/EBIT ratio for Zoetis Inc. (ZTS)?
- The TTM average EV/EBIT ratio for ZTS stock is 17.72x.
- What is the 3Y average EV/EBIT ratio for Zoetis Inc. (ZTS)?
- The 3Y average EV/EBIT ratio for ZTS stock is 23.94x.
- What is the 5Y average EV/EBIT ratio for Zoetis Inc. (ZTS)?
- The 5Y average EV/EBIT ratio for ZTS stock is 27.47x.
- What is the 10Y average EV/EBIT ratio for Zoetis Inc. (ZTS)?
- The 10Y average EV/EBIT ratio for ZTS stock is 28.14x.
Zoetis Inc. EV/EBIT Ratio History
| DATE | EV/EBIT RATIO |
|---|---|
| 2026-06-16 | 11.42x |
| 2026-06-15 | 11.49x |
| 2026-06-12 | 11.45x |
| 2026-06-11 | 11.67x |
| 2026-06-10 | 11.65x |
| 2026-06-09 | 11.76x |
| 2026-06-08 | 11.36x |
| 2026-06-05 | 11.43x |
| 2026-06-04 | 11.44x |
| 2026-06-03 | 11.22x |
| 2026-06-02 | 11.07x |
| 2026-06-01 | 11.21x |
| 2026-05-29 | 11.23x |
| 2026-05-28 | 11.30x |
| 2026-05-27 | 11.44x |
| 2026-05-26 | 11.53x |
| 2026-05-22 | 11.66x |
| 2026-05-21 | 11.51x |
| 2026-05-20 | 11.47x |
| 2026-05-19 | 11.37x |
| 2026-05-18 | 11.23x |
| 2026-05-15 | 10.82x |
| 2026-05-14 | 10.97x |
| 2026-05-13 | 10.83x |
| 2026-05-12 | 11.14x |
| 2026-05-11 | 11.11x |
| 2026-05-08 | 11.83x |
| 2026-05-07 | 12.36x |
| 2026-05-06 | 15.56x |
| 2026-05-05 | 15.72x |
| 2026-05-04 | 15.74x |
| 2026-05-01 | 15.92x |
| 2026-04-30 | 16.02x |
| 2026-04-29 | 15.88x |
| 2026-04-28 | 16.22x |
| 2026-04-27 | 16.37x |
| 2026-04-24 | 16.25x |
| 2026-04-23 | 16.15x |
| 2026-04-22 | 16.33x |
| 2026-04-21 | 16.41x |
| 2026-04-20 | 16.96x |
| 2026-04-17 | 16.92x |
| 2026-04-16 | 16.51x |
| 2026-04-15 | 16.72x |
| 2026-04-14 | 16.76x |
| 2026-04-13 | 16.64x |
| 2026-04-10 | 16.37x |
| 2026-04-09 | 16.63x |
| 2026-04-08 | 16.60x |
| 2026-04-07 | 16.24x |
| 2026-04-06 | 16.42x |
| 2026-04-02 | 16.38x |
| 2026-04-01 | 16.30x |
| 2026-03-31 | 16.41x |
| 2026-03-30 | 16.18x |
| 2026-03-27 | 15.82x |
| 2026-03-26 | 16.22x |
| 2026-03-25 | 16.23x |
| 2026-03-24 | 16.13x |
| 2026-03-23 | 16.05x |
| 2026-03-20 | 16.10x |
| 2026-03-19 | 16.14x |
| 2026-03-18 | 16.31x |
| 2026-03-17 | 16.83x |
| 2026-03-16 | 16.40x |
| 2026-03-13 | 16.10x |
| 2026-03-12 | 16.08x |
| 2026-03-11 | 16.60x |
| 2026-03-10 | 16.69x |
| 2026-03-09 | 16.92x |
| 2026-03-06 | 16.80x |
| 2026-03-05 | 16.90x |
| 2026-03-04 | 17.36x |
| 2026-03-03 | 17.35x |
| 2026-03-02 | 17.72x |
| 2026-02-27 | 17.98x |
| 2026-02-26 | 17.82x |
| 2026-02-25 | 17.72x |
| 2026-02-24 | 17.69x |
| 2026-02-23 | 17.34x |
| 2026-02-20 | 17.70x |
| 2026-02-19 | 17.52x |
| 2026-02-18 | 17.74x |
| 2026-02-17 | 17.31x |
| 2026-02-13 | 17.44x |
| 2026-02-12 | 17.32x |
| 2026-02-11 | 17.59x |
| 2026-02-10 | 17.53x |
| 2026-02-09 | 17.42x |
| 2026-02-06 | 17.44x |
| 2026-02-05 | 17.35x |
| 2026-02-04 | 17.35x |
| 2026-02-03 | 16.81x |
| 2026-02-02 | 17.13x |
| 2026-01-30 | 17.11x |
| 2026-01-29 | 16.72x |
| 2026-01-28 | 16.75x |
| 2026-01-27 | 17.13x |
| 2026-01-26 | 17.00x |
| 2026-01-23 | 17.02x |
| 2026-01-22 | 17.06x |
| 2026-01-21 | 17.14x |
| 2026-01-20 | 16.91x |
| 2026-01-16 | 17.09x |
| 2026-01-15 | 17.17x |
| 2026-01-14 | 17.24x |
| 2026-01-13 | 17.09x |
| 2026-01-12 | 17.18x |
| 2026-01-09 | 17.41x |
| 2026-01-08 | 17.37x |
| 2026-01-07 | 17.22x |
| 2026-01-06 | 17.68x |
| 2026-01-05 | 17.68x |
| 2026-01-02 | 17.25x |
| 2025-12-31 | 17.24x |
| 2025-12-30 | 17.31x |
| 2025-12-29 | 17.26x |
| 2025-12-26 | 17.29x |
| 2025-12-24 | 17.20x |
| 2025-12-23 | 16.95x |
| 2025-12-22 | 16.98x |
| 2025-12-19 | 16.79x |
| 2025-12-18 | 16.85x |
| 2025-12-17 | 16.79x |
| 2025-12-16 | 16.91x |
| 2025-12-15 | 16.63x |
| 2025-12-12 | 16.34x |
| 2025-12-11 | 16.21x |
| 2025-12-10 | 16.27x |
| 2025-12-09 | 15.98x |
| 2025-12-08 | 16.28x |
| 2025-12-05 | 16.34x |
| 2025-12-04 | 16.56x |
| 2025-12-03 | 16.83x |
| 2025-12-02 | 17.06x |
| 2025-12-01 | 17.42x |
| 2025-11-28 | 17.53x |
| 2025-11-26 | 17.47x |
| 2025-11-25 | 17.50x |
| 2025-11-24 | 16.87x |
| 2025-11-21 | 16.77x |
| 2025-11-20 | 15.99x |
| 2025-11-19 | 16.14x |
| 2025-11-18 | 16.28x |
| 2025-11-17 | 16.36x |
| 2025-11-14 | 16.61x |
| 2025-11-13 | 16.65x |
| 2025-11-12 | 16.66x |
| 2025-11-11 | 16.52x |
| 2025-11-10 | 16.48x |
| 2025-11-07 | 16.54x |
| 2025-11-06 | 16.45x |
| 2025-11-05 | 16.57x |
| 2025-11-04 | 17.07x |
| 2025-11-03 | 19.79x |
| 2025-10-31 | 19.76x |
| 2025-10-30 | 19.76x |
| 2025-10-29 | 19.74x |
| 2025-10-28 | 19.93x |
| 2025-10-27 | 20.19x |
| 2025-10-24 | 19.99x |
| 2025-10-23 | 20.05x |
| 2025-10-22 | 20.14x |
| 2025-10-21 | 20.01x |
| 2025-10-20 | 19.88x |
| 2025-10-17 | 19.75x |
| 2025-10-16 | 19.65x |
| 2025-10-15 | 19.51x |
| 2025-10-14 | 19.68x |
| 2025-10-13 | 19.53x |
| 2025-10-10 | 19.38x |
| 2025-10-09 | 19.67x |
| 2025-10-08 | 19.68x |
| 2025-10-07 | 19.59x |
| 2025-10-06 | 19.92x |
| 2025-10-03 | 20.05x |
| 2025-10-02 | 20.06x |
| 2025-10-01 | 20.12x |
| 2025-09-30 | 20.04x |
| 2025-09-29 | 19.63x |
| 2025-09-26 | 19.68x |
| 2025-09-25 | 19.38x |
| 2025-09-24 | 19.45x |
| 2025-09-23 | 19.57x |
| 2025-09-22 | 19.83x |
| 2025-09-19 | 19.98x |
| 2025-09-18 | 20.14x |
| 2025-09-17 | 20.12x |
| 2025-09-16 | 20.18x |
| 2025-09-15 | 20.03x |
| 2025-09-12 | 20.28x |
| 2025-09-11 | 20.58x |
| 2025-09-10 | 20.43x |
| 2025-09-09 | 20.48x |
| 2025-09-08 | 20.73x |
| 2025-09-05 | 20.93x |
| 2025-09-04 | 20.91x |
| 2025-09-03 | 20.81x |
| 2025-09-02 | 20.87x |
| 2025-08-29 | 21.32x |
| 2025-08-28 | 21.11x |
| 2025-08-27 | 21.19x |
| 2025-08-26 | 21.11x |
| 2025-08-25 | 21.16x |
| 2025-08-22 | 21.34x |
| 2025-08-21 | 21.22x |
| 2025-08-20 | 21.36x |
| 2025-08-19 | 21.22x |
| 2025-08-18 | 20.80x |
| 2025-08-15 | 21.03x |
| 2025-08-14 | 20.89x |
| 2025-08-13 | 20.81x |
| 2025-08-12 | 20.48x |
| 2025-08-11 | 20.38x |
| 2025-08-08 | 20.17x |
| 2025-08-07 | 20.28x |
| 2025-08-06 | 20.06x |
| 2025-08-05 | 20.01x |
| 2025-08-04 | 21.25x |
| 2025-08-01 | 20.67x |
| 2025-07-31 | 20.47x |
| 2025-07-30 | 20.86x |
| 2025-07-29 | 21.15x |
| 2025-07-28 | 21.11x |
| 2025-07-25 | 21.29x |
| 2025-07-24 | 21.38x |
| 2025-07-23 | 21.46x |
| 2025-07-22 | 21.17x |
| 2025-07-21 | 20.67x |
| 2025-07-18 | 20.83x |
| 2025-07-17 | 21.02x |
| 2025-07-16 | 21.22x |
| 2025-07-15 | 21.39x |
| 2025-07-14 | 21.75x |
| 2025-07-11 | 21.66x |
| 2025-07-10 | 22.16x |
| 2025-07-09 | 22.09x |
| 2025-07-08 | 22.03x |
| 2025-07-07 | 21.93x |
| 2025-07-03 | 22.21x |
| 2025-07-02 | 22.20x |
| 2025-07-01 | 22.21x |
| 2025-06-30 | 21.79x |
| 2025-06-27 | 21.82x |
| 2025-06-26 | 21.77x |
| 2025-06-25 | 21.96x |
| 2025-06-24 | 22.03x |
| 2025-06-23 | 21.97x |
| 2025-06-20 | 21.95x |
| 2025-06-18 | 21.67x |
| 2025-06-17 | 22.54x |
| 2025-06-16 | 22.89x |
| 2025-06-13 | 22.88x |
| 2025-06-12 | 23.47x |
| 2025-06-11 | 23.14x |
| 2025-06-10 | 23.24x |
| 2025-06-09 | 22.92x |
| 2025-06-06 | 23.64x |
| 2025-06-05 | 23.44x |
| 2025-06-04 | 23.44x |
Showing the most recent 260 of 3,363 data points. The chart above shows the full history.
Related Metrics
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Kristin C. Peck